A new non-invasive technology from LumiThera Inc. may help improve vision in people with dry age-related macular degeneration.
Photobiomodulation involves exposure of the retina to light from diodes emitting red, yellow, and infrared wavelengths. Researchers in Switzerland and Toronto recently found that treating eyes three times a week for three weeks improved best corrected visual acuity by a mean of six to 10 letters in 48%, and 11 to 15 letters in 12% of the 24 subjects enrolled in the trial.
Contrast sensitivity and number and thickness of drusen also improved, with the improvement lasting for three months. Additionally, no new development of geographic atrophy occurred during that period. The treatment utilizes the LT-300 instrument devised by LumiThera.
Based upon these encouraging results, a follow-up study called LIGHTSITE is currently enrolling patients with dry AMD in Canada. The study is partially funded by a NIH National Eye Institute grant.
For more information, visit www.lumithera.com